An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girls

Robine Donken, Johannes A Bogaards, Fiona R M van der Klis, Chris J L M Meijer, Hester E de Melker

Research output: Contribution to journalReview articleAcademicpeer-review


Since 2014, several countries have implemented a 2-dose schedule for Human papillomavirus (HPV) vaccination. Licensure of the 2-dose schedule was based on non-inferiority results from immunobridging studies, comparing the antibody levels of the 2-dose schedule in young girls to those of the 3-dose schedule in young adults. Since licensure, additional data on antibody levels and other aspects of the immune response and clinical effectiveness have become available. This review will discuss the current outcomes on immunogenicity and effectiveness together with an exploration on the population impact of 2-dose schedules from a cost-effectiveness perspective. The 2-dose schedule has important benefits, such as easier logistics, reduced expenditure, potentially higher acceptance and fewer side effects. Policymakers and registration authorities should consider whether these benefits outweigh the likely differences on individual- and population-level impact between the 2- and 3-dose schedules.

Original languageEnglish
Pages (from-to)1381-1393
Number of pages13
JournalHuman Vaccines & Immunotherapeutics
Issue number6
Publication statusPublished - 2 Jun 2016

Cite this